Carboplatin: Difference between revisions
imported>Howard C. Berkowitz No edit summary |
imported>Howard C. Berkowitz No edit summary |
||
| Line 1: | Line 1: | ||
{{subpages}} | {{subpages}} | ||
{{TOC|right}} | {{TOC|right}} | ||
In [[oncology]], '''carboplatin''' is a [[antineoplastic agent]] that is an "organoplatinum compound that possesses antineoplastic activity."<ref>{{MeSH}}</ref> | In [[oncology]], '''carboplatin''' is a [[antineoplastic agent]] that is an "organoplatinum compound that possesses antineoplastic activity."<ref>{{MeSH}}</ref> As compared to [[cisplatin]], carboplatin has equal ([[lung cancer]], [[ovarian cancer]]) or less ([[germ cell tumor]]s, [[bladder cancer]], [[head and neck cancer]]) efficacy but less [[drug toxicity]].<ref name="pmid9541678">{{cite journal| author=Lokich J, Anderson N| title=Carboplatin versus cisplatin in solid tumors: an analysis of the literature. | journal=Ann Oncol | year= 1998 | volume= 9 | issue= 1 | pages= 13-21 | pmid=9541678 | ||
| url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&retmode=ref&cmd=prlinks&id=9541678 }} <!--Formatted by http://sumsearch.uthscsa.edu/cite/--></ref> | |||
Carboplatin was developed specifically to reduce the toxicity of cisplatin. Both are members of what the [[World Health Organization]] calls "other neoplastic agents", specifically class L01XA. <ref>WHO drug database search tool, [http://www.whocc.no/atcddd/indexdatabase/index.php?query=L01XA]</ref> | |||
==History== | ==History== | ||
Revision as of 07:05, 27 June 2010
In oncology, carboplatin is a antineoplastic agent that is an "organoplatinum compound that possesses antineoplastic activity."[1] As compared to cisplatin, carboplatin has equal (lung cancer, ovarian cancer) or less (germ cell tumors, bladder cancer, head and neck cancer) efficacy but less drug toxicity.[2]
Carboplatin was developed specifically to reduce the toxicity of cisplatin. Both are members of what the World Health Organization calls "other neoplastic agents", specifically class L01XA. [3]
History
In the United States, it was approved with a New Drug Application (NDA) by the FDA in 1989.[4] A generic version was approved with a Abbreviated New Drug Application (ANDA) in 2003.[5]
Indications
Human
In the U.S., it is only approved for ovarian carcinoma, but common off-label uses include:[6]
- carcinomas
- endometrial carcinoma
- neuroendocrine prostate carcinoma
- small cell lung carcinoma
- metastatic and locally advanced breast carcinoma
- leukemias
- Unspecified histology
- Malignant Tumor of Cervix
- Malignant Tumor of Head and Neck
- Malignant Tumor of Urinary Bladder
- Non-Small Cell Lung Cancer
- Refractory Malignant Tumor of Testis
- Lymphoma
- Progressive Diffuse Large B-Cell Lymphoma
- Sarcoma
- Refractory Ewing's sarcoma
- Refractory osteosarcoma
- Seminoma of Testis,
Veterinary
It is usually the second chemotherapeutic agent used in feline squamous cell carcinoma.
Dosage
Carboplatin may be dosed by the Calvert formula:[7]
External links
The most up-to-date information about Carboplatin and other drugs can be found at the following sites.
- Carboplatin - FDA approved drug information (drug label) from DailyMed (U.S. National Library of Medicine).
- Carboplatin - Drug information for consumers from MedlinePlus (U.S. National Library of Medicine).
- Carboplatin - Detailed information from DrugBank.
References
- ↑ Anonymous (2024), Carboplatin (English). Medical Subject Headings. U.S. National Library of Medicine.
- ↑ Lokich J, Anderson N (1998). "Carboplatin versus cisplatin in solid tumors: an analysis of the literature.". Ann Oncol 9 (1): 13-21. PMID 9541678.
- ↑ WHO drug database search tool, [1]
- ↑ Drugs@FDA. U S Food and Drug Administration
- ↑ Drugs@FDA. U S Food and Drug Administration
- ↑ Carboplatin, American Society of Health System Pharmacists
- ↑ Calvert AH, Newell DR, Gumbrell LA, O'Reilly S, Burnell M, Boxall FE et al. (1989). "Carboplatin dosage: prospective evaluation of a simple formula based on renal function.". J Clin Oncol 7 (11): 1748-56. PMID 2681557.